← Back to Search

Functional magnetic resonance imaging (fMRI) for Epilepsy

N/A
Waitlist Available
Led By Steven A Messina, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
- Patients who have previously undergone anterior thalamic nucleus deep brain stimulation (DBS) for refractory epilepsy.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up results would be available immediately following processing of the imaging data after each scan
Awards & highlights

Study Summary

This trial will help researchers learn more about how DBS works in the ANT to treat conditions like Parkinson's disease.

Eligible Conditions
  • Epilepsy

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~results would be available immediately following processing of the imaging data after each scan
This trial's timeline: 3 weeks for screening, Varies for treatment, and results would be available immediately following processing of the imaging data after each scan for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Document brain activation networks with ANT stimulation

Side effects data

From 2022 Phase 2 trial • 182 Patients • NCT02966873
19%
Gastrointestinal Discomfort
16%
Viral Upper Respiratory Tract Infections (Cold)
10%
Nausea
10%
Injury
9%
Muscle or Joint Pain
5%
Flatulence
4%
Headache/Migraine
3%
Sinusitis
2%
Pneumonia
2%
Anxiety
2%
Constipation
1%
Stroke
1%
Sepsis
1%
Pancreatitis
1%
Bladder Infection
1%
Injury/Accident
100%
80%
60%
40%
20%
0%
Study treatment Arm
N-Acetylcysteine (NAC) Treatment Group
Placebo Group

Trial Design

1Treatment groups
Experimental Treatment
Group I: Anterior Nucleus of the Thalamus (ANT) Deep Brain Stimulation (DBS)Experimental Treatment1 Intervention
Subjects that have undergone DBS placement for treatment of refractory epilepsy will undergo a fMRI scan. During the fMRI, the subject will undergo alternating short periods of their DBS in the "on" and "off" state with high- and low frequency settings to measure the brain activation changes induced by the DBS.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Functional magnetic resonance imaging (fMRI)
2019
Completed Phase 4
~240

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,183 Previous Clinical Trials
3,759,011 Total Patients Enrolled
22 Trials studying Epilepsy
1,192 Patients Enrolled for Epilepsy
Steven A Messina, MDPrincipal InvestigatorMayo Clinic

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~0 spots leftby May 2024